U.S. infectious diseases group seeks more data on Lilly COVID-19 antibody drug
The medical association, which represents more than 12,000 specialists, said its guidelines panel is evaluating available trial data and will issue its recommendations soon. The Food and Drug Administration on Monday authorized Lilly’s bamlanivimab for people over age 65 recently diagnosed with mild-to-moderate

Full story is loading. Click here if it doesn't...